Anyone care to comment how this might affect (good or bad) EXEL's marketing prospects. EXEL is not mentioned in the article, but DNDN is.
Thanks in Advance,
EXEL is not placing much revenue hopes on the approved prostate indication but rather on Ovarian and others yet to come. BTW: this Motley Fool is just out of college.
Where do you get that from? I think there will be very significant revenue from Prostate Cancer. Nothing out there compares, not Bayer or anyone. IMO